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Overexpression of IL-1a in Skin Differentially
Modulates the Immune Response to Scarification
with Vaccinia Virus
Tian Tian1, Luzheng Liu1, Eva-Jasmin Freyschmidt2, George F. Murphy3, Thomas S. Kupper1 and
Robert C. Fuhlbrigge1,2
Transepidermal inoculation of vaccinia virus (VV), or scarification, has been used effectively for the induction of
specific and long-lasting immunity to smallpox and is superior to other routes of immunization. Scarification of
individuals with atopic skin disease or immune deficiency, however, can lead to persistent viral replication and
result in significant morbidity and mortality. These effects of scarification presumably reflect the unique
immunological properties of skin and the immune cells resident in, or recruited to, the site of inoculation. To
explore these phenomena, we utilized transgenic mice engineered to overexpress IL-1a, a critical mediator of
cutaneous inflammation, in the epidermis. Following scarification with VV, both transgenic and wild-type mice
develop local pox. At high doses of VV, IL-1a transgenic mice recruited immune cells to the inoculation site
more rapidly and demonstrated enhanced T-cell and humoral immune responses. At limiting doses, however,
IL-1a transgenic mice could effectively control virus replication without formation of pox lesions or activation of
a memory response. This study suggests that IL-1 might be useful as an adjuvant to enhance antiviral immunity
and promote safer vaccination strategies; however, understanding the balance of IL-1 effects on innate and
adaptive immune functions will be critical to achieve optimal results.
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INTRODUCTION
Smallpox, caused by variola virus, can be prevented by
immunization with vaccinia virus (VV). Although most
immunizations are delivered by subcutaneous or intramuscular
injection, effective smallpox vaccination requires inoculation
of live VV into the skin—a process termed as scarification—and
the production of an epidermal pox reaction. Although VV
scarification in a normal host results in specific and long-lasting
immunity, in atopic and immunodeficient patients, viral
replication can outstrip immune control, leading to devastating
morbidity and mortality (Bray, 2003). Previous studies have
shown that the balance and interaction of innate and acquired
immune defense mechanisms at the cutaneous interface are
crucial elements that determine the speed and character of the
immune response (Kupper and Fuhlbrigge, 2004). Based on
these observations, we hypothesize that the outcome of
scarification is dependent on the state of immune-response
elements at the site of inoculation, and that manipulation of this
environment can alter the immune response to viral challenge.
Interleukin-1 is a pleiotropic cytokine and a primary
mediator of cutaneous inflammation, serving as an important
link between innate and acquired immune responses
(Dinarello, 1996; Murphy et al., 2000). IL-1 is produced by
many cells in response to infection or activation, and it has
multiple effects, including endothelial activation, enhanced
recruitment of leukocyte, increased production of both
T helper 1 (Th1)- and T helper 2 (Th2)-related cytokines, and
alterations of the hypothalamic thermoregulatory set point.
Adjuvant effects of IL-1 include both increased antibody
production and T-cell memory responses. In humans and in
mice, IL-1 activity is mediated by two homologous cytokines,
IL-1a and IL-1b, that bind the same receptor(s) and elicit
essentially indistinguishable responses mediated by the signal
adaptor protein MyD88. The agonist effects of IL-1a and IL-
1b are balanced by coexpression in all tissues of IL-1 receptor
antagonist. Skin antigen-presenting cells (APCs: monocytes,
macrophages, Langerhans cells, and dendritic cells (DCs))
produce primarily IL-1b. Unstimulated keratinocytes, in
contrast, contain large amounts of preformed and biologically
active IL-1a, as well as significant quantities of immature
IL-1b. Furthermore, keratinocytes also synthesize IL-1 receptor
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antagonist and express the two forms of IL-1 receptors (agonist
receptor (IL-1R1) and decoy receptor (IL-1 R2)). The epidermis,
therefore, is unique in that all elements of the IL-1 axis are
represented. Disruption of this complex regulatory network is
associated with profound inflammatory disease (Dinarello,
1996).
Numerous published studies have explored the biological
consequences of disrupting the natural balance of the IL-1
network in skin by creating transgenic mouse strains that
overexpress IL-1 agonists or antagonists under control of the
human keratin 14 (K14) promoter, which directs expression
to the basal layer of the keratinized epidermis (Vassar et al.,
1989; Groves et al., 1995, 1996; Rauschmayr et al., 1997). In
this study, we have used K14/IL-1a transgenic mice to
examine the influence of increased epidermal IL-1a on the
immune response to vaccinia skin scarification.
RESULTS
T-cell immune response is enhanced and skewed toward Th1 in
K14/IL-1a mice scarified with VV
Keratin 14/IL-1a and wild-type (WT) mice were inoculated by
scarification at the base of the tail with 2106 PFU of
Western reserve (WR)–green fluorescent protein (GFP) virus
and monitored by daily inspection. The vaccination site
became erythematous by day 3 and developed a pustule near
the end of the first week in both WT and transgenic mice.
During the second week, pustules progressed to scab lesions,
which fell off in the third week, leaving a small scar. The
visual appearance and time course of the pox lesions were
similar in these two strains, as well as the C57BL/6 strain (Liu
et al., 2006), and closely resembles local reactions of humans
after scarification. None of these mice showed secondary
pox lesions. T cells harvested from inguinal lymph node (ILN)
and spleen of K14/IL-1a and WT mice and stimulated
with VV-infected APCs showed no induction of IFN-g or
IL-2 production at day 3 after scarification. By day 7, how-
ever, both IFN-g and IL-2 production were increased, with a
substantial enhancement noted in K14/IL-1a mice compared
with WT control mice (Figure 1a). On average, ILN T cells
from K14/IL-1a mice produced threefold more IL-2 (995.8±
40.4 vs 277.5±4.3 pgml1) and eightfold more IFN-g
(28816.7±6840.5 vs 3273.3 ±80.8 pgml1) than WT mice
on day 7 postscarification. Splenic T cells from K14/IL-1a
mice also showed increased cytokine production, but the
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Figure 1. Keratin 14/IL-1a mice develop stronger Th1 immune response following vaccinia scarification compared with WT mice. K14/IL-1a and WT
mice were skin-scarified at the base of their tails with 2 106 PFU of WR-GFP VV. At indicated time points after immunization, purified inguinal LN or
splenic T cells were cultured in vitro with infected syngeneic (APC). (a) IL-2 and IFN-g in the culture supernatant measured after 40 hours. Bars represent
means±SE and are representative of four independent experiments. (b) Frequency of vaccinia-specific T cells measured by IFN-g ELISPOT assay. Data are
expressed as spot-forming cells (SFC) per 106 T cells. Bars represent means±SE and are representative of two independent experiments. *Po0.05, **Po0.01,
***Po0.001; ND, not detected.
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differences were less dramatic. T-cell immune responses
declined rapidly after day 7, with no significant difference in
cytokine production between the two strains seen at 2 weeks
after immunization. Four weeks after immunization, ILN T
cells from both K14/IL-1a and WT mice stimulated with VV-
infected APC produced only trace amounts of cytokines.
Spleen T cells, in contrast, still generated significant amounts
of IL-2 at day 14 and beyond, with no significant difference
documented between transgenic and WT mice. No signifi-
cant increase in IL-4 or IL-10 production was detected from
ILN or splenic T cells from either strain in response to
stimulation with VV-infected APCs (data not shown).
We further evaluated T-cell immunity by enumerating
VV-reactive T cells following scarification using an IFN-g
enzyme-linked immune spot (ELISPOT) assay. T cells were
isolated from spleen and ILN on days 3, 7, 14, and 28 after
scarification, and the frequency of T cells responding to VV-
infected APCs was measured by ELISPOT (Figure 1b).
Consistent with the analysis of cytokine production by ELISA,
the number of VV-specific IFN-g-producing T cells 7 days
after inoculation increased significantly in both the ILN and
the spleen of K14/IL-1a mice relative to WT mice. In ILN, the
number of VV-reactive T cells was greatly reduced at week 2
in both strains, and very few IFN-g-producing T cells could be
detected at 4 weeks after VV inoculation. Although the
number of VV-reactive T cells in spleen also decreased at
week 2, a significant number of IFN-g-producing T cells were
still present 4 weeks after inoculation in both K14/IL-1a and
WT mice. To summarize, both K14/IL-1a and WT mice
demonstrated a Th1-dominated immune response following
VV scarification, with K14/IL-1a mice producing significantly
greater numbers of IFN-g-producing T cells and more Th1
cytokines than WT control mice in the first week after
inoculation.
Production of antibody to VV is enhanced in K14/IL-1a mice
To assess the humoral immune response of K14/IL-1a and WT
mice to VV, serum was collected weekly from day 0 to week
4 and then biweekly from week 6 to week 12 following
scarification. Titer of VV-specific antibody in individual mice
was determined by ELISA. All mice scarified with VV
developed VV-specific IgG after 2 weeks. Antibody responses
peaked at about week 6 and remained stable over the next
6 weeks. K14/IL-1a mice produced vaccinia-specific IgG
earlier and at higher titer in comparison with WT mice.
Measurement of the distribution of IgG subclasses was
used as a surrogate for the Th1 versus Th2 bias of the
immunological response. Although both vaccinia-specific
IgG2a (Th1-associated) and IgG1 (Th2-associated) were
produced after vaccinia scarification, the relatively stronger
induction of IgG2a for all mice indicates a bias toward a Th1
cellular response as a result of VV inoculation (Figure 2).
K14/IL-1a mice recruit T cells and DCs to the site of inoculation
more rapidly than WT mice
To assess lesion development and the kinetics of infiltration
with T cells, we performed immunohistochemical staining of
skin on days 0, 3, 7, and 10 following scarification with VV.
Skin from unimmunized K14/IL-1a and WT mice (day 0) did
not appear significantly different following hematoxylin-and-
eosin or anti-CD3 staining at baseline (data not shown).
Although pox lesions induced by VV scarification of WT and
K14/IL-1a mice did not appear different by gross inspection
(as noted above), there was a substantial difference in the
histological appearance. At day 3 postscarification, scattered
infiltrating cells were seen by hematoxylin-and-eosin stain in
the dermis and hypodermis of WT mice (Figure 3). In
contrast, a dense cellular infiltrate was observed in the skin of
K14/IL-1a mice, particularly in the perifollicular regions.
These infiltrates were composed primarily of mononuclear
cells. Staining for CD3 showed very few T cells at the site of
inoculation in WT mice, whereas strong CD3þ staining was
evident at the site of inoculation in K14/IL-1a mice. Similarly,
although major histocompatibility complex-II (MHC-II)þ
stained cells are seen in WT skin at day 3 postinnoculation,
they are significantly increased (44-fold) in the skin of
K14/IL-1a mice. These cells are in the same perifollicular
distribution as the CD3þ cells. Although some likely
represent activated T cells, many are dendritic in shape and
thus most likely are APCs. Although these findings hold for all
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Figure 2. Kinetics of vaccinia-specific antibody response following scarification with VV. K14/IL-1a and WT mice were skin-scarified at the base of their
tails with 2106 PFU of WR-GFP VV. At various time points after immunization (weekly for weeks 1–4 and biweekly for weeks 6–12), mice from each
group were bled and their sera were collected. Sera were also collected from control, uninfected (week 0) mice. The kinetics of the vaccinia-specific
antibody response in the sera of individual mice at each time point was measured by ELISA. Data represent means±SE using six mice per group and are
representative of four independent experiments. *Po0.05, **Po0.01, ***Po0.001.
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time points examined (days 3, 7, and 10), they were first
evident and most striking on day 3 (data for days 7 and 10 not
shown). These combined data support the impression that
there is a robust cutaneous immune response at the site of
scarification with VV that consists primarily of T cells and
MHC-II-positive APC, and that this response is augmented in
K14/IL-1a mice compared with WT controls. Furthermore,
these data highlight the lack of sensitivity of the gross
appearance of lesions in assessment of the degree and
character of the cutaneous immune response.
Phenotypic maturation of DCs in the draining lymph node is
accelerated in K14/IL-1a mice after VV scarification
To explore the mechanism of enhanced immune response in
K14/IL-1a mice, we examined DC from draining lymph
nodes (LNs) for expression of surface markers related to
DC activation and maturation. CD11cþ cells from LNs of
VV-naive K14/IL-1a mice expressed similar levels of MHC-II,
CD86, and slightly higher levels of CD80 compared with WT
mice, as assessed by flow cytometry (Figure 4). Scarification
with VV resulted in increased expression of all three markers
at 24 hours on CD11cþ cells from K14/IL-1a, but not in WT
mice. At 48 hours postinfection, CD11cþ cells fromWT mice
began to show upregulation of these maturation markers,
but still expressed significantly lower levels than K14/IL-1a
mice. To assess APC functions directly, cell suspensions of
spleen and ILN from VV-naive K14/IL-1a and WT mice were
infected in vitro with VV and cultured for 40 hours with
responder splenocytes from vaccinia-immune WT mice.
Assay of culture supernatants for IFN-g by ELISA showed no
difference in APC function between spleen cells of K14/IL-1a
and WT mice, whereas APCs from skin-draining LNs of K14/
IL-1a mice supported increased IFN-g production relative to
WT LN cells (data not shown). These results support the
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Figure 3. Histology of skin lesions from vaccinia-scarified WT and K14/IL-1a mice. Skin samples from the site of inoculation were obtained from WT and
K14/IL-1a mice 3 days after scarification with 2106 PFU of WR-GFP VV. Formalin-fixed paraffin-embedded tail-skin samples were stained with hematoxylin
and eosin as well as anti-CD3 and anti-Ia (MHC-II) mAb. Labels indicate epidermis (E), proximal follicle (F), and distal follicle (Fd) regions. The data shown
are representative of 3–4 individual mice per experimental group. Bar¼ 250mm.
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hypothesis that excess IL-1a in the epidermis promotes the
maturation of DC draining to the local LNs, which, in turn,
enhances the T-cell immune response to vaccinia scarifica-
tion. In summary, although the size, character, and duration
of pox lesions developing in response to skin scarification
appeared similar in WT and K14/IL-1a mice, functional and
phenotypic analyses of the immune response show a
substantial difference between these strains.
K14/IL-1a mice show a threshold adaptive immune response to
scarification
Based on our observations that excess IL-1a in skin enhanced
the immune response to VV inoculation, we hypothesized
that this would support protection against a lethal challenge
at lower, and presumably safer, doses of VV used for
immunization. To explore this hypothesis, K14/IL-1a mice
and WT mice immunized with high (2106 PFU) or low
(5103 PFU) dose VV WR-GFP by skin scarification were
assessed for resistance to lethal intranasal challenge at 30
days postimmunization. Somewhat surprisingly, whereas a
viral dose of 5 103 PFU/mouse inoculated via scarification
still resulted in pox lesions at the inoculation site in WT mice,
only 50% of K14/IL-1a mice developed pox reactions at this
dose. This observation held through multiple repetitions of
the experiment with careful attention to preparation and
dilution of the viral stock used. Quantitative PCR was used to
assess viral load at the inoculation site. At day 7 postscar-
ification, the number of VV copies present in the skin of K14/
IL-1a mice that developed pox lesions following scarification
with high or low doses of VV were comparable with that of
WT control mice, whereas samples from K14/IL-1a mice that
did not form pox lesions showed significantly diminished
levels of VV DNA (Figure 5a).
This finding was important, as development of a pox lesion
after vaccinia scarification has historically been accepted as
evidence of successful immunization against variola. To
assess the development of protective immune responses,
mice inoculated by scarification with high- and low-dose
vaccinia received an intranasal challenge of 107 PFU of WR
strain VV, a dose that is lethal to nonimmune mice, 5 weeks
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Figure 5. Influence of low-dose VV on protection in mouse challenge models. K14/IL-1a and WT mice were skin-scarified at the base of their tails with
2 106 PFU (high dose) or 5103 PFU (low dose) of WR-GFP VV. All of the WT mice, immunized with either high dose (n¼10) or the low dose (n¼20) VV,
developed pox lesions. Of K14/IL-1a mice immunized with low-dose virus (n¼20), half did not form pox lesions (n¼ 10). (a) Inoculated skin was removed
at 7 days postimmunization and vaccinia viral DNA content was determined by quantitative PCR. This method can detect levels as low as 1 virus copy per mg
DNA. Data shown represent the individual values (symbols), and means (bars) of 9–20 mice per group in two experiments. ***Po0.001, n.s.¼ not significant.
(b) Five weeks after vaccination, mice received an intranasal challenge with 1 107 PFU of VV WR and were weighed daily. The data plotted represent
the means±SE for each group. (c) Vaccinia-specific IgG in the sera of individual mice measured by ELISA 1 month after immunization. Data represent the
means±SE of 4–6 mice per group. ***Po0.001. (d) Thirty-five days postinfection, whole splenocytes were prepared from each mouse and stimulated
with in vitro-infected syngeneic APC. IFN-g in the culture supernatant was measured after 40 hours. Bars represent means±SE for mice in each group.
***Po0.001; n.s., not significant.
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after initial immunization. Sham-immunized K14/IL-1a and
WT mice lost weight rapidly after intranasal challenge and
succumbed to infection or were euthanized (because of
X25% body weight loss) by 7 days postchallenge (data not
shown). In contrast, K14/IL-1a and WT mice immunized with
high-dose (2 106 PFU) VV WR-GFP showed only transient
weight loss and all survived (Figure 5b). Low-dose immuni-
zation (5 103 PFU) also led to protective immunity in WT
mice and in those K14/IL-1a mice that formed pox lesions,
whereas the K14/IL-1a mice that did not develop pox lesions
succumbed to infection with a time course similar to
nonimmunized mice. Thus, development of a pox lesion at
the site of inoculation appeared indicative of an immune
response that resulted in protective immunity. To test this
hypothesis, we measured VV-specific antibody production
and T-cell IFN-g production by WT and K14/IL-1a mice
scarified with high- versus low-dose VV at 1 month
postinoculation. Consistent with the responses seen with
high-dose (2106 PFU) inoculation, K14/IL-1a mice that
developed cutaneous pox lesions when scarified with low-
dose (5 103 PFU) VV had significantly higher vaccinia-
specific antibody titers than did WT controls treated in the
same fashion. However, K14/IL-1a mice that did not form
pox lesions when scarified with low-dose (5 103 PFU) VV
did not show detectable VV-specific antibody at 30 days
postinoculation (Figure 5c). Similarly, production of IFN-g by
splenocytes stimulated with VV-infected APCs at 1 month
postinoculation was comparable for K14/IL-1a mice that
developed pox lesions and WT control mice following
scarification with high or low doses of VV, although
splenocytes of K14/IL-1a mice that did not form pox lesions
did not produce significant IFN-g in response to VV-infected
APC (Figure 5d).
DISCUSSION
In humans, induction of protective immunity to smallpox by
immunization with VV depends on the delivery of virus to the
epidermis by scarification and is characterized by develop-
ment of an epidermal ‘‘pox’’ reaction. Indeed, vaccination by
intradermal, subcutaneous, and intramuscular strategies have
all been shown to result in lower neutralizing antibody titers
and a reduced vaccinia-specific cytotoxic T lymphocyte
response than vaccination by scarification (McClain et al.,
1997). From early in the history of smallpox vaccination, it
has been recognized that certain patient groups are at risk of
complications of the scarification technique (Lofquist et al.,
2003). Vaccinia necrosum, or progressive vaccinia, is seen in
severely immunocompromised patients and leads to severe
morbidity and death from overwhelming infection. Eczema
vaccinatum, which occurs in patients with active or
quiescent atopic dermatitis (AD), reflects an inability of the
atopic host to control the spread of virus from the inoculation
site and can result in substantial tissue injury or death.
Generalized vaccinia infection, which occurs in patients
without AD, is not typically lethal but can also cause
significant injury. Owing to concerns regarding these
complications of vaccine use, and the apparent elimination
of smallpox infection worldwide, widespread vaccination
with VV was halted in the United States in 1972 and world-
wide in the years to follow. Recent concerns about the
possible reemergence of smallpox, or its deliberate release as
a bioterror agent, has led to renewed interest in vaccination
for the armed forces, frontline healthcare personnel, and
perhapsthe general population. At the same time, a relative
increase over the past 30 years in the percent of the world
population with AD, and immune deficiency related to organ
transplantation, chemotherapy treatments, and HIV disease
has spurred interest in understanding the biology of vaccinia-
immune responses and driven efforts to design safer
vaccination protocols.
Although the risks of live viral vaccination in immune-
deficient patients appear obvious, the basis for the severe
adverse effects of vaccinia scarification seen in atopic
patients has not been defined. Vaccination with a live
pathogen inherently involves a ‘‘race’’ between growth and
effective immune response. In the normal host, APCs carrying
antigen migrate from the site of infection through afferent
lymphatics to the draining LNs where they act to prime T
cells. Antigen-specific CD4þ and CD8þ T cells activated in
skin draining LNs become imprinted with a skin-homing
phenotype and will home preferentially to the inoculation
site (Liu et al., 2006), where they can lyse infected target cells
and promote resolution of the infection (Robert and Kupper,
1999). Complications of live pathogen immunization can
result from an inability to respond to a specific infection or an
imbalance that delays control of growth of the pathogen.
Large DNA viruses, including poxviruses and herpesviruses,
commonly encode homologs of cytokines, chemokines, and
their receptors as a strategy to evade the host immune
response (Alcami, 2003). Genes expressed by VV encode
proteins that inhibit complement, bind IL-1 and IL-18, inhibit
CC chemokines, and block IFN function, among others
(Kotwal et al., 1990; Alcami and Smith, 1992; Symons et al.,
1995; Alcami et al., 1998; Smith et al., 2000; Moss and
Shisler, 2001). Together, these viral products alter the
evolution of inflammatory signals and limit the recruitment
of leukocytes to the site of infection, providing the virus with
a crucial advantage in the race with the immune response.
In the case of vaccinia scarification, the balance and
interaction of innate and acquired immune mechanisms in
the skin are crucial. The dose of VV used for scarification has
been empirically optimized such that the immune system of a
normal host usually ‘‘wins,’’ leading to control of virus
growth and long-term immunity. In AD patients, however,
the immune response is altered or inhibited such that VV
replicates faster than the immune system responds, leading to
greater local tissue injury and a risk for dissemination.
Atopic skin, therefore, appears to represent a specialized
environment that promotes VV growth and/or inhibits anti-
viral immunity. Evidence for both functions has been
described. Activation and expansion of cytotoxic anti-viral
T cells, for example, are associated with Th1-type cytokines
(for example,, IL-12 and IFN-g). Atopic skin is characterized,
however, by reduced expression of Th1 cytokines and
increased expression of Th2 cytokines (for example, IL-4
and IL-13) (Hamid et al., 1994). VV infection of human
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keratinocytes has also been shown to induce expression
of Th2-promoting cytokines and other immunoregulatory
factors, including transforming growth factor beta, IL-10, and
IL-13, suggesting that vaccinia may skew local cytokine
production against the generation of a protective Th1 and
cytotoxic T-cell responses (Liu et al., 2005). Innate immune
mechanisms are also altered in atopic hosts. LL-37, as an
example, is a cathelicidin antimicrobial peptide produced by
mammalian skin that exhibits antiviral activity against
purified VV. Recent studies have demonstrated that atopic
skin has decreased LL-37 expression and supports increased
replication of VV compared with normal or psoriasis skin
(Howell et al., 2006). IL-4 and IL-13 treatment of vaccinia-
infected keratinocytes, in turn, enhanced replication of VV,
whereas it downregulates LL-37 expression. These and other
alterations in innate and adaptive immune responses seen in
the skin of atopic individuals may promote local growth of
VV and restrict or delay the expansion or function of Th1 and
Tc1 cells that form the basis of the antiviral response.
As noted previously, the balance of IL-1 agonists and
antagonists plays a central role in the regulation of cutaneous
immune responses (Groves et al., 1995, 1996; Murphy et al.,
2000). It is then, perhaps, not surprising to find inhibitors of
IL-1 function among the immune modulators produced by
vaccinia. The VV gene B15R, for example, encodes a soluble
IL-1 receptor, which binds soluble IL-1b and inhibits
functional responses (Spriggs et al., 1992). Interestingly,
experimental deletion of B15R from VV accelerates the
appearance of symptoms of illness and mortality in mice
infected intranasally with this modified virus, indicating that
some of the adverse effects of respiratory infection may be
related to IL-1 levels in the lung (Alcami and Smith, 1992). In
contrast, immunization with modified VV Ankara with the
soluble IL-1b receptor gene deleted results in a better CD8þ
T-cell memory response and confers higher levels of
protection against subsequent lethal respiratory infection
with WT VV (Staib et al., 2005). Myxoma virus, a poxvirus
that infects rabbits, encodes a protein named M13L-PYD,
which blocks production of the IL-1 family cytokines by
inhibiting caspase-1 activation in the cytoplasmic ‘‘inflam-
masome,’’ thus preventing the maturation of IL-1b from
inactive precursor to active cytokine. Knockout viruses that
do not express this protein are markedly attenuated, showing
decreased viral dissemination and enhanced inflammatory
responses at sites of infection (Johnston et al., 2005).
Similarly, the vaccinia viral gene B13R (SPI-2) encodes a
serpin homolog that inhibits caspase-1. Although deletion of
B13R diminishes virulence, this recombinant virus still
elicited potent humoral, T-cell helper, and cytotoxic T-cell
immune response in the mice (Legrand et al., 2004).
Predicting the effects of vaccinia infection on IL-1 production
and function are even more complex in the context of skin
disease. In patients with atopic skin disease (AD), the ratio of
IL-1 receptor antagonist to IL-1a in stratum corneum samples
from uninvolved skin of the face, trunk, and extremities is
significantly increased due to a decrease in IL-1a and an
increase in IL-1 receptor antagonist production (Terui et al.,
1998). IL-1b mRNA, in contrast, is increased at baseline in
lesional skin from patients with AD and has been shown to
rise in response to patch testing with house dust mite antigen
(Junghans et al., 1998; Jeong et al., 2003). The relative impact
of these competing effects on IL-1 function in the context of
vaccinia scarification is, at present, unknown.
In this study, we used a K14/IL-1a transgenic mouse model
to examine the role and potential benefit of cutaneous IL-1a
as a modulator of immune response to VV inoculated by
scarification. As shown, K14/IL-1a mice scarified with
2106 PFU of vaccinia mounted an earlier and stronger
Th1 immune response and an enhanced humoral immune
response compared with WT control animals. These observa-
tions are consistent with previously reported effects of IL-1 on
Th1 responses in a Leishmania infection model (Filippi et al.,
2003, Von Stebut et al., 2003). K14/IL-1a mice also recruited
T cells and APCs more rapidly to the site of inoculation and
displayed more rapid maturation of DCs arriving at the
draining LNs. The balance of forces affecting innate immune
function was highlighted by results of our studies with
reduced vaccinia inoculation doses. When the dose used for
scarification was decreased to 5,000 PFU, WT mice still
developed pox lesions and produced significant vaccinia-
specific antibody and cell-mediated responses. K14/IL-1a
transgenic mice, however, showed much lower levels of virus
present in the site of inoculation at 7 days, and more than half
did not develop a local pox reaction or show subsequent
evidence of a memory immune response. We hypothesize
that low-dose VV inoculated by scarification in WT mice is
able to suppress the local innate immune response suffi-
ciently to allow limited local growth of virus, leading
ultimately to strong activation of the adaptive immune
response and eventual control of the infection. In K14/IL-1a
mice, in contrast, innate immune function is sufficiently
enhanced to clear the virus in some mice before they can be
growth sufficient to create a pox and/or activate an adaptive
immune response. High-dose inoculation, in contrast, over-
whelms the protective effect of excess IL-1 in the transgenic
animals, resulting in pox lesion formation and strong immune
responses in both WT and IL-1 transgenic mice.
In summary, the observation that epidermal IL-1a
enhances T-cell and antibody responses to VV suggests
that IL-1a could be used as an adjuvant in humans, increasing
the effectiveness of VV inoculation in at-risk populations
and potentially supporting the use of lower inoculation
doses or attenuated virus strains. It is clear, however, that
there is an optimal balance between innate and adaptive
immune function that must be considered in any such
strategy, and that development of a pox lesion may still be
the most suitable indicator of successful, protective immuni-
zation.
MATERIALS AND METHODS
Virus
Recombinant thymidine kinase-negative (TK) VV NP-S-EGFP
(WR-GFP, a kind gift of Dr Bernard Moss, NIH) and TKþ VV WR
strain were expanded in HeLa cells and titered in CV-1 cells
(American Type Culture Collection, Manassas, VA) using standard
procedures (Earl et al., 1998).
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Mice
Wild-type FVB/N mice were purchased from the Jackson Laboratories
(Bar Harbor, ME). The K14/ IL-1a 1.2 line was generated in inbred FVB/
N mice (Groves et al., 1995). Heterozygous transgenic mice from the
K14/IL-1a strain were bred to nontransgenic siblings or to FVB/N WT
mice to produce synchronized delivery of sufficient numbers of animals
for scarification experiments. F1 progeny were screened by PCR with
primers for the transgenic K14 promoter. Mice lacking transgene were
designated as WT littermate controls. As has been described previously,
unstimulated transgenic K14/IL-1amice display only subtle signs of skin
inflammation, such as minor erythema around the snout and mild
alopecia as they age, relative to WT mice. All mice were handled in
accordance with guidelines set out by the Center for Animal Resources
and Comparative Medicine at Harvard Medical School.
Immunizations and challenges
Mice were immunized with VV WR-GFP by scarification as
described (Liu et al., 2006). Briefly, mice were anesthetized with
2,2,2 tribromoethanol (250mg kg1; Sigma, St Louis, MO) by
intraperitoneal injection with a target of 25–30minutes of immobi-
lity. Five microliters of trypsinized virus at varying titers were placed
on the base of the tail. The inoculation site was scarified with a 28-g
needle (500-ml insulin syringe) by poking 25 times and scratching 25
times, endeavoring to stay within the superficial epidermis and to
minimize bleeding. For the high-dose/low-dose studies, a single
aliquot of virus was prepared for use with all mice at each dose (WT
and K14/IL-1a) to minimize the risk of errors in dilution and
handling. For challenge experiments, mice were anesthetized with
isoflurane and inoculated intranasally with 107 PFU of VV WR (10 ml
of 5 108 PFUml1 stock was administered into each nostril). The
individual mice were weighed and checked for survival daily
(Snyder et al., 2004). Mice that lost more than 25% of their body
weight were euthanized.
In vitro restimulation assay
Single-cell suspensions were prepared from ILNs and spleens of
immunized mice. Red blood cells were lysed with lysis buffer (0.15M
NH4Cl, 1mM KHCO3, 0.1mM Na EDTA, pH 7.3). T cells were
purified from infected ILN or spleens using a Pan-T-cell isolation kit
(Miltenyi Biotec, Auburn, CA). In all experiments using T cells, the
purity of the cells was X95% as determined by flow cytometry.
Splenocytes from naive syngeneic mice were infected with VV WR-
GFP at an multiplicity of infection of 20 for 8 hours and irradiated
with 3,300Rad for use as APCs. For stimulation assays, a total of
3 105 purified T cells or whole splenocytes were stimulated with
3 105 infected splenocytes in 96-well flat-bottomed plates. After
40 hours, cytokines in the culture were measured by ELISA (BD
Pharmingen, San Jose, CA).
VV-specific IFN-c ELISPOT
Interferon-g ELISPOT assay was performed using the BD ELISPOT kit
(BD Biosciences, San Jose, CA) according to the manufacturer’s
instructions. Briefly, ELISPOT plates were coated with an anti-IFN-g
mAb (capture mAb) overnight at 4 1C. The plates were washed and
blocked with complete RPMI 1640 with 10% fetal calf serum.
Purified T cells and VV-infected APCs prepared as in the in vitro
restimulation assay were added to the wells and cultured at 37 1C for
40 hours. The plates were washed and a biotinylated anti-IFN-g mAb
was added for 2 hours, followed by washing. Streptavidin-alkaline
phosphatase was added for 1 hour, followed by washing and
development of a color reaction using the 3-amino-9-ethylcarbazole
substrate reagent provided. The reaction was stopped by adding
water, and an immunospot analyzer (Series 3A; Cellular Technology,
Shaker Heights, OH) was used to count the spots (Tian et al., 2005).
Measurement of VV-specific antibody
Vaccinia virus-specific antibody was determined at the indicated
time points by ELISA. A 96-well EIA/RIA plate (cat. no. 3369, Costar,
Lowell, MA) was coated with UV-inactivated VV suspension
containing 105 PFU per well VV WR-GFP in PBS at 4 1C overnight.
The plate was washed and blocked with PBS with 10% fetal calf
serum and 0.05% Tween-20 (PBST) for 2 hours at room temperature.
Serum samples were diluted at 1:200 with PBST and incubated at
4 1C for 1 hour, washed 3 times, and incubated for an additional
1 hour at room temperature with horseradish peroxidase conjugated
goat anti-mouse IgG, IgG1, or IgG2a (Southern). The plate was again
washed and developed using 3,30, 5,50 tetramethylbenzidine (BD
Biosciences) as a substrate. Color development was stopped by
adding 2% H2SO4 to each well. Relative ELISA units were calculated
from the absorbance at 450 nm wavelength (OD450) on a Kinetic
Microplate Reader (Molecular Devices, Sunnyvale, CA).
Quantitative PCR for determination of viral load
Vaccinia viral load was evaluated by quantitative real-time PCR as
described (Freyschmidt et al., 2007). Briefly, inoculated skin and
various organs were harvested at defined time points after scarifica-
tion, and DNA was purified with the DNeasy Mini Kit (Qiagen,
Valencia, CA) according to the manufacturer’s protocol. PCR was
performed with the Bio-Rad iCycler iQTM Real-Time PCR Detection
System (Bio-Rad Laboratories, Hercules, CA). The primers and
TaqMan probe used in the quantitative PCR assay are specific for the
vaccinia ribonucleotide reductase Vvl4L. The sequences of the
primers are as follows: forward, 50-GACACTCTGGCAGCCGAAAT-30;
and reverse, 50-CTGGCGGCTAGAATGGCATA-30. The TaqMan
probe was synthesized by Applied Biosystems (Foster City, CA) with
50-labeled with FAM and 30-labeled with TAMRA. The sequence of
the probe is 50-AGCAGCCACTTGTACTACACAACATCCGGA-30.
Amplification reactions were performed in a 96-well PCR plate
(Bio-Rad) in a 20-ml volume containing 2 TaqMan Master Mix
(Applied Biosystems), 500 nM forward primer, 500 nM reverse primer,
150 nM probe, and the template DNA. Thermal cycling conditions
were 50 1C for 2minutes and 95 1C for 10minutes for one cycle.
Subsequently, 45 cycles of amplification were performed at 94 1C for
15 seconds and 60 1C for 1minute. Viral load was determined by
establishing a standard curve from DNA of a VV stock with a
previously calculated PFU determined by plaque assay. Correspond-
ing cycle threshold values obtained by the real-time PCR methods
were plotted on the standard curve to estimate sample viral load.
Histological analysis
Inoculated skin was harvested from 3–4 mice per group at each time
point. Skin was preserved in formalin, embedded in paraffin,
sectioned, and stained with hematoxylin and eosin, anti-CD3, or
anti-Ia antibody. Images were obtained with a Nikon E600
microscope and a Nikon EDX-35 digital camera. The images were
assembled in Adobe Photoshop 7.0.
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Flow cytometric analysis
Inguinal lymph nodes were excised from immunized mice and a
single-cell suspension prepared by digestion with 250 mgml1
Liberase CI (Roche Applied Science, Indianapolis, IN) in RPMI for
40minutes at 37 1C. Cells were stained with APC-anti-CD11c and
with PE-anti-CD80, PE-anti-CD86, or IA/IE (BD Pharmingen). The
incidence of positive cells and geometric mean fluorescence
intensity were determined by flow cytometry (BD FACSCanto, San
Jose, CA) and analyzed using FACSAria software (BD Biosciences).
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